REVIVA PHARMACEUTICALS HOLDINGS, INC. 8K

Reviva Pharmaceuticals reported Q1 2026 results, strengthened its brilaroxazine IP and development plan, completed a $10 million equity raise, and announced a move from Nasdaq to the OTCQB Venture Market while preparing to start its RECOVER-2 Phase 3 trial.

Reviva Pharmaceuticals Holdings, Inc. reported its unaudited financial results for the quarter ended March 31, 2026, alongside clinical and corporate updates, including the filing of a U.S. composition of matter provisional patent application for a new form of its lead drug candidate brilaroxazine intended to extend patent life and commercial exclusivity potentially through 2046, plans to use this new form in the planned RECOVER-2 registrational Phase 3 schizophrenia trial and future NDA with FDA feedback expected in mid-2026, expected initiation of patient enrollment in RECOVER-2 in the third quarter of 2026, publication of Phase 3 clinical vocal biomarker data in Biological Psychiatry, completion of a $10.0 million public equity offering in March 2026, and the transition of its common stock from a Nasdaq listing to quotation on the OTCQB Venture Market effective May 14, 2026, while disclosing a reduced quarterly net loss of approximately $3.2 million and cash and cash equivalents of approximately $22.2 million as of March 31, 2026.

Filing Facts

CIK

1742927

Ticker

-

Form

8K

Source Type

sec

Accession

0001437749-26-016760

Alert Tier

6